Cited by 81Viral Infectious Diseases and Gene Expression in InsectsVirus-based gene therapy researchRNA Interference and Gene Delivery

Implementation of BacMam virus gene delivery technology in a drug discovery setting

Kost, Thomas A., Condreay, J. Patrick, Ames, Robert S., Rees, Stephen, Romanos, Michael A.·2007·Drug Discovery Today

Abstract

Membrane protein targets constitute a key segment of drug discovery portfolios and significant effort has gone into increasing the speed and efficiency of pursuing these targets. However, issues still exist in routine gene expression and stable cell-based assay development for membrane proteins, which are often multimeric or toxic to host cells. To enhance cell-based assay capabilities, modified baculovirus (BacMam virus) gene delivery technology has been successfully applied to the transient expression of target proteins in mammalian cells. Here, we review the development, full implementation and benefits of this platform-based gene expression technology in support of SAR and HTS assays across GlaxoSmithKline.

Integrity signals

Registry

Crossref · 10.1016/j.drudis.2007.02.017

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kost, T. A., Condreay, J. P., Ames, R. S., Rees, S., & Romanos, M. A.
Affiliations
  • GlaxoSmithKline (United States) (US)
  • GlaxoSmithKline (United Kingdom) (GB)
Corresponding author
Kost, Thomas A.
Venue
Drug Discovery Today
Publisher
Elsevier BV
Published
2007-05
Volume
12
Issue
9-10
Pages
396-403
ISSN
1359-6446 (ISSN-L)
OpenAlex
W1999603524
Cited by
81
References
1
Citations by year
2026: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 3 · 2015: 6 · 2014: 4 · 2013: 5 · 2012: 5
FWCI
0.85
Type
journal article
Language
en
Open access
closed
Locations
  • Drug Discovery Today (publishedVersion)
  • PubMed (publishedVersion)
Funders
GlaxoSmithKline
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
membrane proteins, transient protein expression, mammalian cells, cell-based assays, structure-activity relationship, high-throughput screening, drug discovery
MeSH terms
Animals, Drug Industry, Genetic Vectors, Humans, Models, Biological, Technology, Pharmaceutical, Transfection, Drug Design, Gene Expression, Baculoviridae

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review